Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841894 | 0.88 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL21775973 | 0.86 | MAPK1 (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL12264366 | 0.86 | MAPK1 (0.47) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL14997805 | 0.86 | DAO (0.45) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL12210930 | 0.86 | MAPK1 (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL25451234 | 0.86 | MAPK1 (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL12737778 | 0.84 | MAPK1 (0.41) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL279712 | 0.82 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL498360 | 0.82 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL14379745 | 0.82 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428202-A1 | PROCESS OF PRODUCING POLYOLEFINS USING METALLOCENE POLYMERIZATION CATALYSTS AND COPOLYMERS THEREFROM | ExxonMobil Chemical Patents Inc. (US) | 2019-01-16 | — | — | EP | claimed |
| US-9611348-B2 | Process of producing polyolefins using metallocene polymerization catalysts and copolymers therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-04-04 | — | — | US | claimed |
| EP-2984111-A1 | PROCESS OF PRODUCING POLYOLEFINS USING METALLOCENE POLYMERIZATION CATALYSTS AND COPOLYMERS THEREFROM | ExxonMobil Chemical Patents Inc. (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140316085-A1 | Process of Producing Polyolefins Using Metallocene Polymerization Catalysts and Copolymers Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2014-10-23 | — | — | US | claimed |
| WO-2014169017-A1 | PROCESS OF PRODUCING POLYOLEFINS USING METALLOCENE POLYMERIZATION CATALYSTS AND COPOLYMERS THEREFROM | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-10-16 | — | — | WO | claimed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024085690-A1 | CURRENT COLLECTOR FOR ELECTRODE | 주식회사 엘지화학 | 2024-04-25 | — | — | WO | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240018279-A1 | Cyclic Containing Polymer Compositions Obtained Using Transition Metal Bis(Phenolate) Catalyst Complexes and Process for Production Thereof | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-7335753-B2 | Bifunctional heterocyclic compounds and methods of making and using same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20080020127-A1 | Methods and systems for coating a medical device | ALLACCEM, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021212-A1 | Methods and systems for preparing an antimicrobial composition | ALLACCEM, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070202342-A1 | Applying to an oral surface (teeth or gums)one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning; dentistry; bonding agents, resin cements, sealants | ALLACCEM, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070072811-A1 | Bifunctional heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-5234790-A | Peel-apart photosensitive element | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MAPK1 1068/4885KMT2A 4004/4885YEATS4 1243/4885 |
| US-20070072811-A1 | Bifunctional heterocyclic compounds and methods of making and using the same | PCNA, DCX, HPGDS | MAPK1 2437/4885KMT2A 4064/4885YEATS4 3858/4885 |
| US-20080021212-A1 | Methods and systems for preparing an antimicrobial composition | DNMT1, TET2, POLR1C | MAPK1 3686/4885KMT2A 1094/4885YEATS4 3989/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | MAPK1 2729/4885KMT2A 1342/4885YEATS4 984/4885 |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | MAPK1 4123/4885KMT2A 2669/4885YEATS4 3905/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | MAPK1 4148/4885KMT2A 3060/4885YEATS4 3814/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | MAPK1 2648/4885KMT2A 3647/4885YEATS4 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.